Basal Cell Carcinoma News and Research RSS Feed - Basal Cell Carcinoma News and Research

Basal cell cancer begins in the lowest layer of the epidermis, the basal cell layer. About 8 out of 10 skin cancers are basal cell carcinomas. They usually begin on areas exposed to the sun, such as the head and neck. Basal cell carcinoma was once found mostly in middle-aged or older people. But now it is also being seen in younger people. This may be because people are spending more time in the sun without protecting their skin.

Basal cell carcinoma tends to grow slowly. It is very rare for a basal cell cancer to spread to distant parts of the body (metastasize). But if it is not treated, it can grow into nearby areas and spread into the bone or other tissues beneath the skin.

After treatment, basal cell carcinoma can come back (recur) in the same place on the skin. New basal cell cancers can also start in other places on the skin. As many as half of the people who have one basal cell cancer will get a new skin cancer within 5 years.
Anti-TNF therapy linked to ‘modest’ extra SCC risk

Anti-TNF therapy linked to ‘modest’ extra SCC risk

A Swedish population-based study shows that treatment with tumour necrosis factor inhibitors significantly increases the risk of developing squamous cell carcinoma, but not basal cell carcinoma, in patients with rheumatoid arthritis. [More]
New radiotherapeutic bandage shows promise against squamous cell carcinoma in animal model

New radiotherapeutic bandage shows promise against squamous cell carcinoma in animal model

A radiotherapeutic bandage is being evaluated by researchers for efficacy against squamous cell carcinoma (SCC) in an animal model. These results could confirm the viability of a new and improved strategy for the radiotherapeutic treatment of skin cancer in the clinic. This work is being presented Oct. 28 at the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Orlando, Fla. Oct. 25-29. [More]
Michelson Diagnostics’ VivoSight OCT scanner provides accurate diagnosis of early-stage BCC, reduces skin biopsies by 36%

Michelson Diagnostics’ VivoSight OCT scanner provides accurate diagnosis of early-stage BCC, reduces skin biopsies by 36%

Michelson Diagnostics, a medical device company focused on applications of multi-beam Optical Coherence Tomography technology, today announces data showing that use of its VivoSight OCT scanner significantly improves diagnosis of basal-cell carcinoma at an earlier stage and reduces diagnostic biopsies by 36%. [More]
Roflumilast drug could inhibit growth of brain tumor in children

Roflumilast drug could inhibit growth of brain tumor in children

Current drugs may stop working against the most common type of brain tumor in children, medulloblastoma, but the tumor could be targeted in a new way, according to Stanford University scientists. [More]
HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial. [More]
Vismodegib therapy effective against medulloblastoma

Vismodegib therapy effective against medulloblastoma

A targeted therapy already used to treat advanced skin cancer is also effective against the most common subtype of the brain tumor medulloblastoma in adults and should be considered for treatment of newly diagnosed patients, according to research led by St. Jude Children's Research Hospital. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

New understanding of keratin 17 protein could lead to development of better ways to prevent cancer

New research from the Johns Hopkins Bloomberg School of Public Health suggests that the protein keratin 17 - the presence of which is used in the lab to detect and stage various types of cancers - is not just a biomarker for the disease, but may play a critical role in tumor growth. [More]
Elekta's Esteya electronic brachytherapy improves outcomes in patients with basal cell carcinoma

Elekta's Esteya electronic brachytherapy improves outcomes in patients with basal cell carcinoma

Physicians at La Fe University and Polytechnic Hospital - Valencia presented their early clinical outcome data on the use of Esteya electronic brachytherapy for the treatment of basal cell carcinoma in a paper in the current issue of Journal of Contemporary Brachytherapy. The ongoing study showed 100 percent complete response and excellent cosmetic outcome in all lesions treated to date with Esteya. [More]
Skin Cancer Awareness Recommended For HCT Recipients

Skin Cancer Awareness Recommended For HCT Recipients

Patients who undergo haematopoietic cell transplantation should be educated on the risk of skin cancer and the need for regular self-examination, US researchers say. [More]
New laser technology shows promise for cancer treatment

New laser technology shows promise for cancer treatment

Surgeons rely on 200-year-old technology when removing cancer--sight and touch--to determine how much to remove and what to leave alone. Laser technology pioneered at Florida Atlantic University has the promise to help a surgeon better determine if an area is cancer or healthy tissue. Moreover, when combined with laser treatment for cancer, this work lays the groundwork for laser robotic treatment of cancer. [More]
Scientists potentially discover new therapeutic targets to halt progression of tumor cells

Scientists potentially discover new therapeutic targets to halt progression of tumor cells

Chronic inflammation is directly associated with several types of cancer, yet the reasons as to why this happens at a cellular level remain unclear. Now, an international team of scientists led by researchers at The Wistar Institute has identified a multistep process showing not only how these cancers develop but also potentially discovering new therapeutic targets that could halt the formation and progression of tumor cells. [More]
Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an update on the clinical trial pipeline for its lead immunotherapy products treating basal cell carcinoma (BCC) and breast cancer. [More]
Exposure to ultraviolet radiation lamps used for indoor tanning increases risk of developing BCC

Exposure to ultraviolet radiation lamps used for indoor tanning increases risk of developing BCC

Dartmouth researchers have found that early exposure to the ultraviolet radiation lamps used for indoor tanning is related to an increased risk of developing basal cell carcinomas (BCC) at a young age. [More]
EU-funded project aims to identify potential new targets for cancer therapy

EU-funded project aims to identify potential new targets for cancer therapy

Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner. [More]
Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell carcinoma (mBCC) taking the investigational oral compound LDE225 (sonidegib) had marked and sustained tumor shrinkage after a median follow-up of 13.9 months. [More]

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, has commenced a clinical study to investigate the use of OCT to diagnose basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system. [More]
Skin Cancer Awareness Month and Melanoma Monday: Mount Sinai experts to share vital skin cancer tips

Skin Cancer Awareness Month and Melanoma Monday: Mount Sinai experts to share vital skin cancer tips

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers. In recognition of May's Skin Cancer Awareness Month and Melanoma Monday on May 5th, Mount Sinai Health System experts are arming the public with vital tips on prevention and offering FREE skin cancer screenings. [More]
Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). [More]
Ascend Biopharmaceuticals reports favourable results from TG1042 Phase 2 study for CBCL treatment

Ascend Biopharmaceuticals reports favourable results from TG1042 Phase 2 study for CBCL treatment

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has today announced the publication of a report utilising TG1042 (ASN-002) for the treatment of Cutaneous B-Cell Lymphoma (CBCL), in the journal PLOS ONE. [More]
Advertisement